Dianthus Therapeutics【DNTH】銘柄情報

Dianthus Therapeutics Inc (DNTH) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

81.385

( -0.62% )

買値

81.11

売値

81.59

出来高

302,254

79.79 日の範囲 85.00

16.635 52 週間の範囲 96.5033

時価総額

4.449B

前日終値

81.89

始値

83.64

時刻

81.4622

最終取引時間

02:36:02

財務取引量

US$ 24,910,632

VWAP

82.4162

平均取引量 (3 か月)

US$ 824,215

発行済株式数

54,666,233

配当利回り

PER

-19.7

1 株当たり利益 (EPS)

-4.17

歳入

1.34M

純利益

-173.66M

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

dianthustx.com

本社

New York, United States

設立

2026

Dianthus Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker DNTH. The last closing price for Dianthus Therapeutics was US$81.89. Over the last year, Dianthus Therapeutics shares have traded in a share price range of US$ 16.635 to US$ 96.5033.

Dianthus Therapeutics currently has 54,666,233 shares in issue. The market capitalisation of Dianthus Therapeutics is US$4.45 billion. Dianthus Therapeutics has a price to earnings ratio (PE ratio) of -19.70.

Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases

Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	4.575	5.95625569587	76.81	85	74.43	1073762	80.05283875	CS
4	-6.195	-7.07353277004	87.58	93.61	68.8483	1018420	82.07153302	CS
12	0.775	0.961419178762	80.61	96.5033	68.8483	779760	84.81710127	CS
26	39.495	94.2826450227	41.89	96.5033	35.84	855715	70.63863627	CS
52	64.235	374.548104956	17.15	96.5033	16.635	728720	54.94737478	CS
156	70.985	682.548076923	10.4	96.5033	6.58	386111	44.79717554	CS
260	70.985	682.548076923	10.4	96.5033	6.58	386111	44.79717554	CS